2-[(1S,2R,10S,11S,14R,15S,17S)-14,17-dihydroxy-2,15-dimethyl-5-oxotetracyclo[8.7.0.02,7.011,15]heptadeca-3,6-dien-14-yl]-2-oxoethyl 2,2-dimethylpropanoate

• ChemBase ID: 179850
• Molecular Formular: C26H36O6
• Molecular Mass: 444.56044
• Monoisotopic Mass: 444.25118887
• SMILES: [C@]12([C@@](C(=O)COC(=O)C(C)(C)C)(CC[C@H]1[C@H]1[C@@H]([C@@]3(C(=CC(=O)C=C3)CC1)C)[C@H](C2)O)O)C
• Canonical SMILES: O=C1C=C[C@]2(C(=C1)CC[C@@H]1[C@@H]2[C@@H](O)C[C@]2([C@H]1CC[C@]2(O)C(=O)COC(=O)C(C)(C)C)C)C
• InChI: InChI=1S/C26H36O6/c1-23(2,3)22(30)32-14-20(29)26(31)11-9-18-17-7-6-15-12-16(27)8-10-24(15,4)21(17)19(28)13-25(18,26)5/h8,10,12,17-19,21,28,31H,6-7,9,11,13-14H2,1-5H3/t17-,18-,19-,21+,24-,25-,26-/m0/s1
• InChIKey: PHEOVVDXTQVHAZ-XDANTLIUSA-N

NAMES AND DATABASE IDS

Names

• IUPAC name: 2-[(1S,2R,10S,11S,14R,15S,17S)-14,17-dihydroxy-2,15-dimethyl-5-oxotetracyclo[8.7.0.0^2,^7.0^1^1,^1^5]heptadeca-3,6-dien-14-yl]-2-oxoethyl 2,2-dimethylpropanoate
• IUPAC Traditional name: 2-[(1S,2R,10S,11S,14R,15S,17S)-14,17-dihydroxy-2,15-dimethyl-5-oxotetracyclo[8.7.0.0^2,^7.0^1^1,^1^5]heptadeca-3,6-dien-14-yl]-2-oxoethyl 2,2-dimethylpropanoate
• Synonyms: Mecortolon; Ultracortenol; Ultracorterenol; Vecortenol; Prednisolone trimethylacetate

Database IDs

• CAS Number: 1107-99-9
• PubChem SID: 164235760
• PubChem CID: 10095005

CALCULATED PROPERTIES

• Acid pKa: 12.610195
• H Acceptors: 5
• H Donor: 2
• LogD (pH = 5.5): 3.5136516
• LogD (pH = 7.4): 3.513649
• Log P: 3.5136518
• Molar Refractivity: 121.3472 cm^3
• Polarizability: 47.390816 Å^3
• Polar Surface Area: 100.9 Å^2
• Rotatable Bonds: 5
• Lipinski's Rule of Five: true

PROPERTIES

Pharmacology Properties

• Mechanism of Action: ACTH antagonist; ACTH secretion inhibitor; Adrenocortical steroid; Calcium mobilizer; Gluconeogenesis promoter; Glycogen deposition inhibitor; Phosphorus mobilizer.

Product Information

• Application(s): Antiallergic agent; Antiinflammatory; Immunosuppressive

REFERENCES

• Aldrich Library of 13C and 1H FT NMR Spectra, 1992, 3, 585B, (nmr)
• Nobile, A. et al., J.A.C.S., 1955, 77, 4184, (biosynth)
• Herzog, H.L. et al., Science (Washington, D.C.), 1955, 121, 176, (struct)
• Zicha, L. et al., Arzneim.-Forsch., 1960, 10, 728; 831, (pharmacol, derivs)
• Herzog, H.L. et al., Tetrahedron, 1962, 18, 581, (synth)
• Hirschmann, R. et al., J.A.C.S., 1964, 86, 3903, (synth)
• Toft, P. et al., Can. J. Spectrosc., 1970, 15, 137, (ms)
• Gambertoglis, J.G. et al., J. Pharmacokinet. Biopharm., 1980, 8, 1, (rev, pharmacol)
• Jusko, W.J. et al., Ther. Drug Monit., 1980, 2, 169, (rev, pharmacol)
• Gonzalez, M.D. et al., Org. Magn. Reson., 1984, 22, 586, (cmr)
• Negwer, M., Organic-Chemical Drugs and their Synonyms, 6th edn., Akademie-Verlag, 1987, 6297; 6321; 6941
• Kirk, D.N. et al., J.C.S. Perkin 2, 1990, 1567, (pmr)
• Ali, S.L., Anal. Profiles Drug Subst., 1992, 21, 415, (rev)
• Martindale, The Extra Pharmacopoeia, 30th edn., Pharmaceutical Press, 1993, 737
• Lewis, R.J., Sax's Dangerous Properties of Industrial Materials, 8th edn., Van Nostrand Reinhold, 1992, AAF625; PMA000; PMA100; SOV100; PLY300